Distinct Inflammation Biomarkers in Healthy Individuals and Patients with Schizophrenia: A Reliability Testing of Multiplex Cytokine Immunoassay by Bland-Altman Analysis

Ta-Chuan Yeh1, Hsuan-Te Chu2, Chia-Kuang Tsai3,4, Hsin-An Chang1, Fu-Chi Yang3, San-Yuan Huang1,4, and Chih-Sung Liang2,4

1Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
2Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
3Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
4Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, Republic of China

Objective Since the inflammatory process has been implicated in the pathophysiology of psychiatric disorder, an important issue emerging is to assess the test-retest reliability of cytokine measurement in healthy individuals and patients with schizophrenia. The objective of the present study was to investigate the test-retest reliability of bead-based multiplex immunoassay technology (BMIT) for cytokine measurement by using a Bland-Altman plot (BAP).

Methods Twenty healthy individuals and twenty patients with schizophrenia were enrolled, and a 17-plex cytokine assay was used to measure inflammatory biomarkers at baseline and two weeks later. The test-retest reliability was examined by BAP, 95% limits of agreement (LOA), intraclass correlation coefficient (ICC), and coefficient of repeatability (CoR).

Results In the healthy controls, only interleukin (IL)-2, IL-13, IL-10, IL-17, and macrophage inflammatory protein-1β showed excellent ICC. The BAP with 95% LOA determined that 13 cytokines showed acceptable 95% LOA for a 2-week test-retest reliability, and only IL-1β, IL-12 and tumor necrosis factor (TNF)-α had significant test-retest bias. The CoR of cytokines varied significantly, ranging from 1.72 to 218.1. Compared with healthy controls, patients with schizophrenia showed significantly higher levels of IL-5, IL-13, and TNF-α and significantly lower levels of IL-4, IL-12, and interferon-gamma (IFN-γ). Of these six cytokines, IL-12 and TNF-α were considered suboptimal reliability.

Conclusion The findings from ICC and CoR implied that the test-retest reliability of BMIT for cytokine measurement were suboptimal. However, the BAP with 95% LOA confirmed that BMIT can reliably distinguish schizophrenia from healthy individuals in cytokine measurement, while significant within-subject variation and between-group overlapping were evident in cytokine expression.

Key Words Multiplex immunoassay, Cytokine, Reliability, Inflammation, Schizophrenia.
ties are noted and suggested to be independent of medication. Evidence therefore suggests an ongoing immune process in patients with schizophrenia, and this population may have a unique inflammatory profile compared to healthy controls. The distinct trajectories of cytokine levels may be indicated to be trait or state markers. Trait markers, like interleukin (IL)-12, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) remain elevated despite the treatment. On the contrary, IL-1β, IL-6, and TNF-α appear to be state markers which return to the baseline level after symptoms of exacerbation were resolved. As a first step in understanding the inflammation in schizophrenia, it would be helpful to investigate the equality between quantitative measurements of inflammatory markers on BMIT, or it would lead to inaccurate estimations and faulty conclusions.

Some authors have recommended using a Bland-Altman plot (BAP) and 95% limits of agreement (LOA) to assess the test-retest reliability. The graphic approach shows the association of difference in cytokine levels against the mean value of paired measurements for each subject. By constructing an agreement interval with 95% of the differences, a BAP provides more information on the range of variability between measurements for each cytokine.

To date, little data exists on the reliability and agreement of BMIT in measuring cytokine levels. The principle aim of this study is to examine the reliability and agreement of BMIT (17-plex panel) on repeated measurements by using BAPs, 95% LOA, intraclass correlation coefficient (ICC), and coefficient of repeatability (CoR). The secondary aim is to compare the cytokines showing optimal test-retest reliability in patients with schizophrenia with those of healthy controls.

METHODS

Study population
A total of 40 subjects were recruited in Taipei city, northern Taiwan, including 20 patients with schizophrenia and 20 healthy controls. All of the patients were hospitalized in a chronic ward with stable psychiatric condition for more than six months. The control group were enrolled using advertisement, such as leaflets and internet. Patients were interviewed by two certified psychiatrists to confirm the diagnosis of schizophrenia based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Healthy controls were interviewed as well to exclude a diagnosis of psychiatric disorder. One previous report clearly indicated the confounding effect of body weight index (BMI) on the levels of cytokines and chemokines. Moreover, gender and aging can affect inflammatory profiles. To eliminate potential confounding factors, the study only enrolled male subjects aged from 20–40 years and with BMI <30 kg/m².

The exclusion criteria were as follows: 1) a history of major medical or neurological disorder; 2) previous head trauma with loss of consciousness; 3) a diagnosis of substance-related disorders; 4) a history of heavy tobacco use or heavy alcohol consumption; and 5) cigarette smoking or alcohol drinking in the most recent three months. Tobacco use and alcohol consumption were not allowed during the study period.

The study procedures were approved by the Institutional Review Board for the Protection of Human Subjects at the Tri-Service General Hospital, a medical teaching hospital within the National Defense Medical Center in Taiwan (TSGH IRB No. 2-103-05-096). Written informed consent was obtained in accordance with the National Health and Medical Research Council guidelines. All participants fully understood the study protocol and all details involved. They were free to withdraw their consent at any time.

Cytokine measurement
Venous blood samples were obtained by venipuncture in the morning between 8:00 and 9:00 AM in fasting status. For the preparation of plasma samples, 10 mL of peripheral blood was drawn into an EDTA-containing Vacutainer Tube and immediately centrifuged to separate the plasma (1,000×g at 4°C for 10 min). The samples were then placed into NUNC-cryovial tubes and stored at -84°C. For BMIT assays, thawed aliquots were gently vortexed and then centrifuged at 13,200 rpm for 10 min at 4°C immediately prior to testing. Repeated sampling from healthy controls was performed 14 days later.

The multiplex magnetic bead-based antibody 17-plex panel (Bio-Plex® by Bio-Plex Pro™, Catalog #MS00031YV) was used to analyze samples according to the manufacturer's instructions on BMIT analyzers (Bio-Plex 200, Genmab Biotechnology Co., LTD., Taipei, Taiwan). The surveyed cytokines were: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte/Macrophage Colony Stimulating Factor (GM-CSF), IFN-γ, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-beta (MIP-1β), and TNF-α. Several cytokines are classified as chemokines, including CC chemokines [CCL2 (MCP-1), CCL4 (MIP-1β), and CXCL8 (IL-8)]. Standard curves were created from duplicate values and all samples were analyzed as single determinations. The coefficient of variation was below 10% for intra-assay and below 15% for inter-assay.

Statistical analysis
BAP was drawn, which can quantify agreement in test-retest design. Bias was calculated as the mean of test-retest change values, which is the average test-retest difference. Significant
bias was considered to exist if the 95% confidence interval (CI) of bias did not include the value of zero or if the Wilcoxon signed-rank test reached significance. 95% LOA for each test-retest difference was calculated as bias ±1.96 × the standard deviation (SD) of the paired difference. Agreement between repeated measurements made on the same subject depends only on the within-subject SD. The range of the upper and lower LOA reflected how far apart the repeated measurements differences were likely to be for most individuals. 95% CIs of upper and lower LOA were calculated by taking each limit plus or minus the product of 1.96 and standard error.22 CoR referred to as the smallest real difference was calculated as 1.96 × \sqrt{2} × within-subject SD, which can quantify repeatability and reproducibility. ICC was calculated from the proportion of total variability due to between-subject variability. Rosner's interpretation of ICC was applied: ICC <0.40 indicates poor reliability, ICC between 0.40 and 0.75 reflects fair to good reliability, and ICC ≥0.75 reflects strong reliability.22 An ICC of at least 0.55 has been recognized as meaningful and worth further consideration.23 Group differences in demographic characteristics were analyzed by Mann-Whitney U tests. Data on cytokines were transformed using the natural logarithms for general linear regression analysis. BMI and age were analyzed as covariates and worth further consideration.23

RESULTS

Bias with 95% CI

Table 1 displays the baseline and post-test levels of cytokines and bias with 95% CI in healthy controls. The result of repeated measurements by Wilcoxon signed-rank test determined that IL-1β, IL-7, and IL-12 were significantly varied over time, with the greatest difference for IL-1β (p<0.01). After a 14-day interval, most cytokines did not show significant bias; however, IL-1β, IL-12, and TNF-α had significant bias, as their 95% CI did not contain the value of zero. The bias was -1.18 to -0.27 pg/mL for IL-1β, -15.52 to -0.87 pg/mL for IL-12, and -6.79 to -0.29 pg/mL for TNF-α.

Table 1. Bias, 95% limits of agreement, repeatability coefficient, and intraclass correlation coefficient for 14-day repeated cytokine level (pg/mL) measurements in 20 healthy controls

| Cytokines | Baseline | Re-test | p* | Bias | 95% CI of bias | Upper LOA | Lower LOA | CoR with 95% CI | ICC | Outlier |
|-----------|----------|---------|----|------|----------------|-----------|-----------|----------------|-----|---------|
| IL-1β     | 2.08±1.08| 1.35±0.95| <0.01 | -0.73 | -1.18 to -0.27 | 1.19 | -2.64 | 2.35 (1.79–3.39) | 0.54 | 2       |
| IL-2      | 6.72±9.30| 5.70±6.92| 0.45 | -1.02 | -3.27 to -1.24 | 8.43 | -10.46 | 9.42 (7.21–13.61) | 0.83 | 2       |
| IL-4      | 3.60±1.64| 3.08±1.38| 0.31 | -0.52 | -1.32 to -0.29 | 2.87 | -3.9  | 3.45 (2.64–4.98)  | 0.35 | 1       |
| IL-5      | 4.31±2.09| 3.44±1.40| 0.06 | -0.87 | -1.77 to -0.03 | 2.9  | 4.64  | 4.05 (3.10–5.85)  | 0.41 | 1       |
| IL-6      | 10.28±5.15| 8.45±4.58| 0.28 | -1.83 | -4.42 to -0.77 | 9.03 | -12.68 | 11.17 (8.54–16.13) | 0.36 | 0       |
| IL-7      | 11.28±15.77| 6.13±2.18| 0.02 | -5.15 | -12.48 to -2.19 | 25.56 | -35.85 | 31.58 (24.16–45.61) | 0.03 | 1       |
| IL-8      | 15.17±5.63| 12.88±5.78| 0.13 | -2.30 | -5.09 to -0.5  | 9.41 | -14   | 12.26 (9.38–17.71) | 0.45 | 0       |
| IL-10     | 22.32±13.27| 17.88±10.67| 0.12 | -4.43 | -9.75 to 0.88  | 17.84 | -26.7 | 23.38 (17.89–33.76) | 0.55 | 1       |
| IL-12     | 30.82±17.53| 22.62±13.87| 0.02 | -8.2  | -15.52 to -0.87 | 22.49 | -38.88 | 33.95 (25.97–49.02) | 0.19 | 0       |
| IL-13     | 2.31±1.37| 2.09±1.39| 0.11 | -0.21 | -0.62 to 0.2  | 1.5  | -1.93 | 1.72 (1.32–2.49)  | 0.8  | 1       |
| IL-17     | 16.44±12.75| 13.73±13.33| 0.25 | -2.71 | -7.54 to 2.13  | 17.55 | -22.96 | 20.44 (15.64–29.52) | 0.69 | 1       |
| G-CSF     | 25.92±9.87| 23.12±10.77| 0.25 | -2.8  | -7.64 to -2.03 | 17.47 | -23.07 | 20.51 (15.69–29.61) | 0.5  | 0       |
| GM-CSF    | NA       | NA       | NA  | NA   | NA             | NA   | NA      | NA             | NA  | NA      |
| IFN-γ     | 242.42±112.24| 227.65±113.89| 0.60 | -14.77 | -67.72 to 38.18 | 206.97 | -236.52 | 218.06 (166.83–314.9) | 0.5  | 0       |
| MCP-1     | 13.29±3.93| 12.94±2.98| 0.84 | -0.36 | -2.15 to -1.44 | 7.16 | -7.88  | 7.36 (5.63–10.63)  | 0.4  | 1       |
| MIP-1β    | 40.49±9.37| 40.76±12.66| 0.81 | 0.26  | -3.76 to -4.29 | 17.13 | -16.6 | 16.44 (12.58–23.75) | 0.7  | 1       |
| TNF-α     | 13.24±7.75| 9.7±5.61 | 0.05 | -3.54 | -6.79 to -0.29 | 10.08 | -17.16 | 14.98 (11.46–21.62) | 0.47 | 2       |

*p-test retest differences were examined by Wilcoxon signed-rank test; outlier was defined as paired samples value exceeding range of CoR and 95% LOA; and cytokines with bold text indicate significant changes in re-test measurement or 95% CI of bias across zero. CoR: coefficient of repeatability, ICC: intraclass correlation coefficient, IL: interleukin, G-CSF: granulocyte colony-stimulating factor, GM-CSF: granulocyte-macrophage colony-stimulating factor, IFN-γ: interferon gamma, LOA: limit of agreement, MCP-1: monocyte chemotactic protein 1, MIP: macrophage inflammatory protein, TNF-α: tumor necrosis factor alpha

www.psychiatryinvestigation.org 609
Reliability and agreement

The data of 95% LOA, CoR, and ICC are shown in Table 1. The upper LOA indicates the most likely maximum increase in value on post-test measurement, and the lower LOA shows decrease in value. Considering the ICC, IL2, and IL-13 showed excellent reproducibility (ICC ≥ 0.75); IL-10, IL-17, and MIP-1β exhibited good reproducibility (ICC > 0.55); IL-4, IL-6, IL-7, and IL-12 had poor reproducibility (ICC < 0.40). The number of outliers is shown in the last column of the table. An outlier is a value exceeding the range of CoR and 95% LOA. Figure 1 illustrates the result of BAP. In each plot, bias and variance are taken into account with respect to the mean value of cytokines which correspond to the vertical line. A total of 14 outliers were noted (14/320 = 4.37%). The proportion of all cytokines within 95% LOA was 95.63%. Figure 2 illustrates the cytokines that reached between-group significance and did not have significant bias. Patients with schizophrenia revealed dissimilar cytokine expression compared to healthy controls; however, overlapping intervals were evident for IL-4 and IL-13 (Supplementary Figure 1 in the online-only Data Supplement).

![Figure 1. Bland-Altman plots for repeat measurements of multiplex cytokine assay in 20 healthy controls. The Bland-Altman plots represent the difference of repeated measurements of cytokine levels against the average value for each pair of measurements. The solid line is the mean difference; a mean difference of zero means no change in cytokine levels after a 14-day interval. The two dotted lines represent the 95% limits of agreement for the upper and lower limits of agreement. IL: interleukin, G-CSF: granulocyte colony-stimulating factor, IFN-γ: interferon gamma, MCP-1: monocyte chemotactic protein 1, MIP: macrophage inflammatory protein, TNF-α: tumor necrosis factor alpha.](image-url)
Demographic data and baseline levels of cytokines

Table 2 shows the demographic characteristics and baseline levels of cytokines. Compared with healthy controls, patients with schizophrenia were significantly older, and their BMI was significantly larger. Of the 17 cytokines, most data on GM-CSF were under the lower limit of detection and were excluded from the final analysis. The dispersion of cytokine levels was large for patients with schizophrenia and healthy controls. For example, in healthy controls, the mean of IL-7 was 11.28 pg/mL, while its SD was 15.77 pg/mL; in patients with schizophrenia, the mean of TNF-α was 50.16 pg/mL, while its SD was 101 pg/mL. Considering between-group differences, patients with schizophrenia had significantly higher levels of IL-5, IL-13, and TNF-α, and significantly lower levels of IL-4, IL-12, and IFN-γ.

DISCUSSION

This study showed that by using BMIT for cytokine measurement, the within-subject cytokine variation was large, making the test-retest reliability suboptimal by testing ICC. When using BAPs with 95% LOA, most cytokines had acceptable test-retest reliability; only 4.37% of cytokine data were considered outliers, and only three cytokines showed significant bias. Although most cytokine expression in patients with schizophrenia was distinct from that of healthy controls (Supplementary Figure 1 in the online-only Data Supplement), the large within-subject and between-group variation in cytokine levels led to only four cytokines showing optimal test-retest reliability and reaching between-group differences.

A previous study used ICC to examine the test-retest reliability of BMIT in measuring cytokine levels in healthy individuals and patients with major depression. However, the authors found that the levels of cytokines varied differently in health participants during a 30-week interval, implying sub-optimal test-retest reliability of BMIT. Importantly, ICC is the fraction of the total variance attributed to between-subject variability. Assuming that there are no systematic biases, ICC is affected primarily by heterogeneity of subjects. However, if within-subject variability is comparable to or even larger than between-subject variability, the degree defined by the ICC becomes meaningless. In other words, if the normal range of cytokine levels varies significantly on repeated measurements in the same individual, ICC is not an appropriate indicator of between-subject differences, as the within-subject variance may be larger than the between-subject variance. By using BAPs to assess the test-retest reliability of BMIT, a large proportion of cytokine data were still within 95% LOA without significant bias. This means that future research using a larger sample size can help reframe representative levels for each cytokine, and the results of BMIT for cytokine measurement can

Table 2. Demographic data and baseline levels of cytokines and chemokines in patients with schizophrenia and healthy controls

|                | Schizophrenia (N=20) | Healthy controls (N=20) | p*   |
|----------------|----------------------|-------------------------|------|
| Age           | 46.60±8.88           | 28.05±3.59              | <0.01|
| BMI           | 25.49±4.33           | 23.11±1.76              | 0.01 |
| IL-1β         | 3.02±3.18            | 2.08±1.08               | 0.15 |
| IL-2          | 3.77±3.87            | 6.72±9.3                | 0.67 |
| IL-4          | 1.69±0.63            | 3.60±1.64               | <0.03|
| IL-5          | 9.96±5.39            | 4.31±2.09               | <0.01|
| IL-6          | 8.61±5.48            | 10.28±5.15              | 0.69 |
| IL-7          | 7.17±3.12            | 11.28±5.77              | 0.87 |
| IL-8          | 8.58±3.97            | 15.17±5.63              | 0.05 |
| IL-10         | 10.27±7.91           | 22.32±13.27             | 0.10 |
| IL-12         | 8.95±5.43            | 30.82±17.53             | <0.01|
| IL-13         | 13.10±11.26          | 2.31±1.37               | <0.01|
| IL-17         | 18.83±14.01          | 16.44±12.75             | 0.43 |
| G-CSF         | 23.88±13.31          | 25.92±9.87              | 0.54 |
| IFN-γ         | 75.30±22.66          | 242.42±112.24           | <0.01|
| MIP-1β        | 17.21±10.85          | 13.29±3.93              | 0.62 |
| MIP-1β*       | 31.46±15.5           | 40.49±9.37              | 0.19 |
| TNF-α         | 50.16±10             | 13.24±7.75              | 0.01 |

*age and BMI were analyzed by Mann-Whitney U tests; cytokines (pg/mL) were transformed using the natural logarithms and analyzed by a general linear model with covariates of age and BMI. BMI: body mass index, IL: interleukin, G-CSF: granulocyte colony-stimulating factor, GM-CSF: granulocyte-macrophage colony-stimulating factor, IFN-γ: interferon gamma, MCP-1: monocyte chemotactic protein 1, MIP: macrophage inflammatory protein, TNF-α: tumor necrosis factor alpha

www.psychiatryinvestigation.org 611
determine reliable biomarkers for exploring the link between psychiatric disorders and the inflammatory process.

Our findings support optimal test-retest reliability for several cytokines assayed by BMIT, including IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, G-CSF, GM-CSF, IFN-γ, MCP-1, and MIP-1β. For these cytokines, the lines of equality (zero) were within 95% CI of bias, implying reliable agreement over a 14-day test-retest interval. However, the difference of retest on IL-7 needs to be emphasized, as the CoR was relatively large (31.58, 95% CI: 24.16 to 45.61 pg/mL), and the Wilcoxon signed-rank test reached significance. On the other hand, IL-1β and IL-12 appeared to have larger intra-individual variation than those of other cytokines, as both cytokines showed significant cytokine changes on retest and significant bias on BAPs. Previous studies compared the immunoassay results between an enzyme-linked immunosorbent assays (ELISA) and BMIT for cytokine measurements, revealing robust correlations for IL-1β, IL-7, and IL-12,26,27 however, whether these cytokines could reach optimal test-retest reliability remains unknown. The results from our study suggest that even in healthy controls, these cytokines may respond to the external environment in a very sensitive way, resulting in large intra-individual variation in cytokine levels.24,26

The ICC for IL-4 (0.35), IL-6 (0.36), and IL-7 (0.03) in our study showed discrepancy from those of a previous study in which ICC was larger than 0.90 over a 30-day interval.23 By definition, ICC represents inter-individual variability relative to total variability. Because the within-subject variation in cytokine levels was large in healthy controls, the lower ICCs in our study suggest that within-subject variability may be larger than between-subject variability, constituting a small ratio of between-subject variability over total variability. BAPs with 95% LOA can help address how far apart the true repeated measurement differences were likely to be on BMIT for cytokine measurements. For example, the ICC was 0.35 for IL-4, indicating poor differentiating ability. Using BAPs with 95% LOA, the upper LOA was 2.87 pg/mL and the lower LOA was -3.9 pg/mL. This means that the changes in IL-4 levels on retest measurement ranged from -3.9 to 2.87 pg/mL. The value of CoR was 3.45 pg/mL for IL-4, which also represented the measurement error or the smallest possible change on repeated measurements by BMIT.

In the current study, patients with schizophrenia had significantly higher levels of IL-5 and IL-13, and significantly lower levels of IL-4 and IFN-γ, which appeared not to support the schizophrenia theory of T helper (Th)2 shifting (IL-4, IL-5, and IL-13,) and blunted Th1 (IL-2, IL-12, INF-γ, and TNF-α). A meta-analysis reported significant decrease in IFN-γ levels in a chronic schizophrenia subgroup with a large effect size (Hedge’s= -1.07), which was consistent with our findings.28 However, another study found that IFN-γ levels did not change with clinical severity, and suggested that INF-γ is a trait marker that continually increased expression in the disease course.8 IL-5 and IL-13, as anti-inflammatory cytokines produced by Th2 cells, were inclined to increase in our study. On the other hand, in our study, IL-4 was lower; however, Goldsmith et al.28 and O’Brien et al.29 have found IL-4 to be associated with acute schizophrenia episodes. The discrepancy between our study and the previous meta-analyses can be explained by the heterogeneity of the included studies in the meta-analyses. For example, the inclusion criteria did not distinguish studies which collected serum samples from plasma. However, plasma levels of cytokine measurements have been reported to be higher than the serum levels.24,30,32 Moreover, these studies did not address limitations of the standard assays, such as the multiplex system or ELISA based system, and previous evidence has revealed discordant results between these methods which may result in substantial heterogeneity while conducting meta-analysis.28,33

A strength in our study is that we have confirmed the test-retest agreement for numerous important cytokines on BMIT using plasma samples, which can assist further research in exploring these cytokine biomarkers or performing meta-analytical work. However, our findings should be interpreted carefully with consideration of the following limitations. First, our sample size was small, so the 95% LOA and 95% CI of bias were wide. For example, in the levels of IFN-γ, the Wilcoxon signed-rank test did not show significant difference on the repeated measurement and the BAP did not determine a significant bias; however, the CoR of IFN-γ was 218.06 pg/mL, with 95% CI ranging from 166.83 to 314.90 pg/mL. Another limitation is that we did not stratify the patient groups by clinical features or treatments due to the small sample size. A previous meta-analysis has analyzed the cytokine differences by subgrouping into first-episode psychosis and medicated patients to eliminate the effects of psychotropics.8 Third, a small sample size may increase within-subject variation in cytokine expression. Fourth, although we found agreement on cytokine measurements by BMIT, the participants in our study were homogenous in nature. A larger study can stratify different patient groups by clinical features or treatments and analyze subgrouping BAP with 95% LOA, which can provide deeper insight into cytokine variation and define their reference range.

In conclusion, this study provides evidence that BMIT has good reproducibility and test-retest reliability on cytokine measurements. Patients with schizophrenia demonstrated aberrant cytokine expression compared to healthy individuals, and their inflammatory profiles can be distinguished by selecting
reliable cytokines. Currently, the use of cytokines as potential disease markers is still limited. Knowledge of the stability of plasma cytokines levels based on BMIT will help researchers to better delineate inflammatory profiles between different populations.

Supplementary Materials

The online-only Data Supplement is available with this article at https://doi.org/10.30773/pi.2019.04.14.

Acknowledgments

Funding for this study was provided by Civilian Administration Division of Belto Branch, Tri-Service General Hospital (TSGH-BT-104-04; TSGH-BT-106-005). The Civilian Administration Division had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Ta-Chuan Yeh, Chih-Sung Liang. Data curation: Hsuan-Te Chu. Formal analysis: Fu-Chi Yang. Funding acquisition: Chih-Sung Liang. Validation: San-Yuan Huang. Visualization: Ta-Chuan Yeh. Writing—original draft: Ta-Chuan Yeh. Writing—review & editing: Chih-Sung Liang.

ORCID iDs

Chih-Sung Liang https://orcid.org/0000-0003-1138-5586
Ta-Chuan Yeh https://orcid.org/0000-0002-1016-3634

REFERENCES

1. Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2015;2:258-270.
2. Potvin S, Stip E, Sepephy AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008;63:801-809.
3. Watanabe Y, Someya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 2010;64:217-230.
4. Chu CS, Li DJ, Chu CL, Wu CC, Lu T. Decreased IL-1ra and NCAM-1/CD56 serum levels in unmedicated patients with schizophrenia before and after antipsychotic treatment. Psychiatry Investig 2018;15:727-732.
5. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 2001;58:1032-1037.
6. Mortensen PB, Norgaard-Pedersen B, Waltoft BL, Sorensen TL, Hougaard D, Torrey EF, et al. Tauxplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol Psychiatry 2007;61:688-693.
7. Nielsen PB, Agerbo E, Skogstrand K, Hougaard DM, Meyer U, Mortensen PB. Neonatal levels of inflammatory markers and later risk of schizophrenia. Biol Psychiatry 2015;77:548-555.
8. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663-671.

9. Bevan-Jones WR, Surendranathan A, Passamonti L, Vazquez Rodriguez P, Arnold R, Mak E, et al. Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. BMJ Open 2017;7:e013187.
10. Roiz-Santizanez R, Crespo-Facorro B, Perez-Iglesias R, Pelayo-Teran JM, Carrasco-Marín E, Mata I, et al. Interleukin-1 receptor antagonist genotype and brain morphometry in first-episode non-affective psychosis. Psychiatry Res 2008;162:167-171.
11. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001;49:1-52.
12. Barch DM, Carter CS, Braver TS, Sabb FW, MacDonald A 3rd, Noll DC, et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry 2001;58:280-288.
13. Glahn DC, Ragland JD, Abramoff A, Barrett J, Laird AR, Bearden CE, et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Mapp 2005;25:60-69.
14. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Lumines and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods 2009;340:55-64.
15. Müller N, Schwarz MJ. Immune system and schizophrenia. Curr Immunol Rev 2010;6:213-220.
16. Berchtold A. Test-retest: agreement or reliability? Method Innov 2016; 9:1-7.
17. Ho PS, Huang SY, Liang CS. Limitations of measuring blood cytokines in biological psychiatry. Psychoneuroendocrinology 2017;78:253.
18. Myles PS, Cui JL. Using the Bland-Altman method to measure agreement with repeated measures. Br J Anaesth 2007;99:309-311.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, DSM-IV-TR. Washington DC, American Psychiatric Association; 2000.
20. Larsson A, Carlsson L, Lind AL, Gohdib T, Bodekka C, Kamali-Moghadam M, et al. The body mass index (BMI) is significantly correlated with levels of cytokines and chemokines in cerebrospinal fluid. Cytokine 2015;76:514-518.
21. Larsson A, Carlsson L, Gohdib T, Lind AL, Thulin M, Kamali-Moghadam M. The effects of age and gender on plasma levels of 63 cytokines. J Immunol Methods 2015;425:58-61.
22. Bartlett JW, Frost C. Reliability, repeatability and reproducibility: analysis of measurement errors in continuous variables. Ultrasound Obstet Gynecol 2008;31:466-475.
23. Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L, et al. Reproducibility of serum cytokines and growth factors. Cytokine 2009;45:44-49.
24. Belzeaux R, Lefebvre MN, Lazzari A, Le Carpentier T, Consoloni JL, Zendjijian X, et al. How to: measuring blood cytokines in biological psychiatry. Psychoneuroendocrinology 2017;78:253.
25. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 2016;15:155-163.
26. Churchman S, Geiler J, Parmar R, Horner E, Church L, Emery P, et al. Multiplexing immunoassays for cytokine detection in the serum of patients with rheumatoid arthritis: lack of sensitivity and interference by rheumatoid factor. Clin Exp Rheumatol 2012;30:345-346.
27. duPont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of lumines multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 2005;66:175-191.
28. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016;21:1696-1709.
29. O’Brien SM, Scully P, Dinan TG. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res 2008;160:256-262.

30. Altara R, Manca M, Hermans KC, Daskalopoulos EP, Brunner-LaRocca HP, Hermans RJ, et al. Diurnal rhythms of serum and plasma cytokine profiles in healthy elderly individuals assessed using membrane-based multiplexed immunoassay. J Transl Med 2015;13:129.

31. Chaturvedi AK, Kemp TJ, Pfeiffer RM, Biancotto A, Williams M, Munuo S, et al. Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiol Biomarkers Prev 2011;20:1902-1911.

32. Rosenberg-Hasson Y, Hansmann L, Liedtke M, Herschmann I, Maecker HT. Effects of serum and plasma matrices on multiplex immunoassays. Immunol Res 2014;58:224-233.

33. Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. Elisa and multiplex technologies for measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci 2008;63:879-884.
Supplementary Figure 1. Distribution of baseline cytokines of patients with schizophrenia and healthy controls.